All In Biotech

Drug Trial Radar · NCT06961786

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

A Phase 1, Open-label, Single-arm Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of TNFa and IL-2 Coding Oncolytic Adenovirus TILT-123 in Combination With Lymphocyte-depleting Chemotherapy and Tumor-infiltrating Lymphocytes in Melanoma Patients.

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Jun 25, 2025

Primary completion

Nov 2026

Study completion Apr 2027

Sponsor

Lead sponsor
TILT Biotherapeutics Ltd.Industry
Sponsor type
Industry
First posted
May 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.

Conditions

  • Metastatic Melanoma

Interventions

  • TILT-123Biological

    TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

  • TILBiological

    Adoptive T cell therapy with TILs

  • CyclophosphamideDrug

    Lymphocyte-depleting chemotherapy

  • FludarabineDrug

    Lymphocyte-depleting chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with any (serious and non-serious) Adverse EventsTime frame: 78 days
  2. Number of Participants with abnormal laboratory valuesTime frame: 78 days
  3. Number of Participants with vital sign abnormalitiesTime frame: 78 days
  4. Safety assessed by 12- lead electrocardiograms (ECGs) Adverse EventsTime frame: 78 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.